{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:15:24Z","timestamp":1760645724894},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T00:00:00Z","timestamp":1268265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Accurate knowledge of tumour presence and location is essential to treat neuroendocrine tumours (NETs). Standard imaging has been hampered by low sensitivity and lack of spatial resolution. This study assessed prospectively the diagnostic value and impact of combined 6-[18F]fluorodihydroxyphenylalanine positron emission tomography\u2013computed tomography (18F-DOPA-PET\/CT) in the management of NET.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>18F-DOPA-PET\/CT findings in 61 patients with suspected NET were compared with a composite reference standard including somatostatin receptor scintigraphy (SRS), magnetic resonance imaging, computed tomography, histological examination and clinical follow-up. The impact on clinical management was estimated by calculating the proportion of patients whose treatment changed as a result of 18F-DOPA-PET\/CT findings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>18F-DOPA-PET\/CT correctly identified 32 of 36 patients with NET. The sensitivity and specificity of 18F-DOPA-PET\/CT for the detection of NET were 91 and 96 per cent respectively. Sensitivity using SRS was significantly lower (59 per cent), whereas the specificity was similar (86 per cent). In 16 (26 per cent) of the 61 patients the management was altered as a result of new findings on 18F-DOPA-PET\/CT.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>18F-DOPA-PET\/CT yields a high sensitivity and specificity in the detection of NET. The clinical impact was highly relevant as changes in therapy were observed in more than a quarter of the patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.6937","type":"journal-article","created":{"date-parts":[[2010,3,11]],"date-time":"2010-03-11T14:53:21Z","timestamp":1268319201000},"page":"691-697","source":"Crossref","is-referenced-by-count":31,"title":["Value of combined 6-[18F]fluorodihydroxyphenylalanine PET\/CT for imaging of neuroendocrine tumours"],"prefix":"10.1093","volume":"97","author":[{"given":"M","family":"Schiesser","sequence":"first","affiliation":[{"name":"Department of Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Veit-Haibach","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M K","family":"Muller","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bauerfeind","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Hany","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P-A","family":"Clavien","sequence":"additional","affiliation":[{"name":"Department of Surgery, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"2021070910455538500_bib1","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/oxfordjournals.annonc.a010633","article-title":"Neuroendocrine gastrointestinal tumours","volume":"7","author":"Oberg","year":"1996","journal-title":"Ann Oncol"},{"key":"2021070910455538500_bib2","volume-title":"Surveillance, Epidemiology, and End Results (SEER) Program: SEER Stat Database","author":"National Cancer Institute","year":"2007"},{"key":"2021070910455538500_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1196\/annals.1294.002","article-title":"The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification","volume":"1014","author":"Kl\u00f6ppel","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"2021070910455538500_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021070910455538500_bib5","first-page":"1455","article-title":"Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?","volume":"47","author":"Montravers","year":"2006","journal-title":"J Nucl Med"},{"key":"2021070910455538500_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2003.01885.x","article-title":"SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours","volume":"59","author":"Krausz","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021070910455538500_bib7","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0016-5085(98)70282-3","article-title":"Somatostatin receptor scintigraphy: a first-line imaging modality for gastroenteropancreatic neuroendocrine tumors","volume":"115","author":"Lebtahi","year":"1998","journal-title":"Gastroenterology"},{"key":"2021070910455538500_bib8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-125-1-199607010-00005","article-title":"Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study","volume":"125","author":"Gibril","year":"1996","journal-title":"Ann Intern Med"},{"key":"2021070910455538500_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1148\/radiology.220.2.r01au25373","article-title":"Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors","volume":"220","author":"Hoegerle","year":"2001","journal-title":"Radiology"},{"key":"2021070910455538500_bib10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2967\/jnumed.107.045708","article-title":"6-l-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications","volume":"49","author":"Jager","year":"2008","journal-title":"J Nucl Med"},{"key":"2021070910455538500_bib11","first-page":"432","article-title":"Radiolabeled amino acids: basic aspects and clinical applications in oncology","volume":"42","author":"Jager","year":"2001","journal-title":"J Nucl Med"},{"key":"2021070910455538500_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.sla.0000172095.97787.84","article-title":"Positron emission tomography\/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness","volume":"242","author":"Heinrich","year":"2005","journal-title":"Ann Surg"},{"key":"2021070910455538500_bib13","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2967\/jnumed.107.041947","article-title":"18F-DOPA PET and PET\/CT","volume":"48","author":"Nanni","year":"2007","journal-title":"J Nucl Med"},{"key":"2021070910455538500_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.dld.2008.03.015","article-title":"Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas","volume":"41","author":"Bettini","year":"2009","journal-title":"Dig Liver Dis"},{"key":"2021070910455538500_bib15","first-page":"889","article-title":"Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy","volume":"43","author":"Lebtahi","year":"2002","journal-title":"J Nucl Med"},{"key":"2021070910455538500_bib16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1470-2045(06)70801-4","article-title":"Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study","volume":"7","author":"Koopmans","year":"2006","journal-title":"Lancet Oncol"},{"key":"2021070910455538500_bib17","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1007\/s00259-007-0498-y","article-title":"The added value of [18F]fluoro-l-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children","volume":"34","author":"Ribeiro","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021070910455538500_bib18","first-page":"1161","article-title":"Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET","volume":"45","author":"Becherer","year":"2004","journal-title":"J Nucl Med"},{"key":"2021070910455538500_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00000658-199808000-00013","article-title":"Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger\u2013Ellison syndrome","volume":"228","author":"Alexander","year":"1998","journal-title":"Ann Surg"},{"key":"2021070910455538500_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68 Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J Nucl Med"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.6937","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/97\/5\/691\/36640691\/bjs6937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/97\/5\/691\/36640691\/bjs6937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T20:13:29Z","timestamp":1625861609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/97\/5\/691\/6142110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2010,3,11]]},"published-print":{"date-parts":[[2010,4,9]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.6937","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,5]]},"published":{"date-parts":[[2010,3,11]]}}}